slogan: Recombinant monoclonal antibodies and membrane proteins for drug discovery.
The company's innovative offerings include the DiMPro™ Membrane Protein Platform, DimAb® Single B Cell Antibody Discovery Platform, DiLibrary™ Mammalian Display Antibody Engineering Platform, and DiAssay™ Antibody Evaluation Platform. Its last investment, an Angel Round, was in September 2019, with funding from Emerging Technology Partners, Guoqian Venture Capital, and Huatai Zijin Investment. Dima Biotechnology aims to accelerate drug discovery for the Biopharma sector, fostering innovation and expediting life-changing therapy development.
Dima Biotechnology
Recombinant monoclonal antibodies and membrane proteins for drug discovery.
Founded 2018
Rockville, United States
6 employees
Angel
Biotechnology, Health Care
Rockville, United States
6 employees
Angel
Biotechnology, Health Care
General Information
Get notified when Dima Biotechnology moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track Dima Biotechnology
Get real-time alerts for funding, hiring, news, and 40+ signal types.
Start Tracking — FreeDiscover More
United States Market
Biotechnology
About Dima Biotechnology
Taxonomy: Biotech, Monoclonal Antibodies, Membrane Proteins, Drug Discovery, Preclinical R&D, Biopharma Research, Antibody Technology, Mammalian Cell Expression, GPCRs, Ion Channels, B Cell Antibody Discovery, Antibody Engineering, Screening Processes, Therapy Development, Innovation
Funding Rounds & Investors (1)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Angel Round | Unknown | 3 |
|
11 Sep 2019 |
Dima Biotechnology Alternatives & Competitors
Dima Biotechnology vs
Integral Molecular
United States
The Industry Leader In Membrane Protein Solutions
Grant
94 employees
Biotechnology
Dima Biotechnology vs
ACYTE Biotech supplies proprietary mammalian cell lines and technologies to enhance cell engineering...
2 employees
Dima Biotechnology vs
Sino Biological, Inc.
United States
Global Leader in Recombinant Technology for the Life Sciences
IPO
269 employees
Also compare with:
vs
Harbour BioMed
vs
Harbour BioMed
FAQ About Dima Biotechnology
Recombinant monoclonal antibodies and membrane proteins for drug discovery.
Dima Biotechnology was founded in 2018.
Dima Biotechnology is headquartered in Rockville, United States.
Dima Biotechnology operates in the following industries: Biotechnology, Health Care.
Dima Biotechnology has approximately 6 employees.
Dima Biotechnology has completed 1 funding round. The latest funding stage is Angel.
Top alternatives and competitors to Dima Biotechnology include Integral Molecular, ACYTE Biotech, Sino Biological, Inc., Harbour BioMed, Ablexis, LLC. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Dima Biotechnology and Integral Molecular are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.
Don't just browse. Track.
Signal Tracker monitors Dima Biotechnology and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.